New Medical Device Regulation

Managing the transition to the new regulation: this is a seminar you cannot afford to miss as you put in place your strategies for the new environment.

25-26 Sep 2018

& 5-6 Mar 2019

GBP 1,499
EUR 2,099
USD 2,338

Book now

Course overview

The New Medical Device Regulation (MDR) brings about a period of great change, uncertainty and opportunity within the medical technology and diagnostics sectors. This seminar will help you embrace these changes and operate successfully in the new environment in Europe. It will cover in depth the new regulations and their implementation by the Member States and Notified Bodies. You will get to hear the latest thoughts on clinical development, safety monitoring and the implications of Brexit.

Who should attend

  • Regulatory affairs
  • Clinical studies
  • Vigilance
  • PMS
  • Quality systems
  • Technical support and business development.

Why you should attend

This seminar will provide key guidance and interpretation of the changes to the regulation and will be of value to all those who are involved in placing a medical device on the market, and anyone who requires an essential overview of the new medical device regulation and its impact on the industry and working practices.

Programme Day One

09.30 Chairman’s welcome and introduction

09.45 Introduction and background to the new regulation

  • Medical Device Co-ordination Groups
    Dr David Jefferys

10.45 Discussion

11.00 Refreshments

11.30 Key Preparation for successful implementation

  • Where, what, how?
  • A road map for the new regulation
  • EUDAMED database – maximizing the potential
  • Implications of Brexit
    Graeme Tunbridge

12.30 Discussion

12.45 Lunch

13.45 Notified Bodies: How the changes will impact NBs and manufacturer’s – including the new rules for IVD conformity assessment

  • Accreditation and designation of NBs
  • How to register with NBs
  • Conformity assessment applications
    Theresa Jeary

15.00 Discussion

15.10 Refreshments

15.30 Increased vigilance and Post Market Surveillance – how to comply

  • Post Market Surveillance systems appropriate for your device and risk classification
  • Periodic Safety Update Reports (PSURs)
  • Manufacturer’s response times to serious public health threats and deaths caused by devices
    Dr David Jefferys

16.45 Discussion

17.00 Close of day one

Programme Day Two

09.00 Welcome to day two

09.30 Clinical investigations – what is required?

  • Greater protection for patients participating in clinical investigations
  • Products to have an acceptable benefit to risk ratio
  • Product safety and performance
  • Changes in data requirements
  • Restrictions by individual Member States
    Janette Benaddi

10.30 Discussion

10.45 Refreshments

11.15 IVDs and companion diagnostics

  • Implications and timelines
  • New IVD conformity assessment rules
    Theresa Jeary

12.30 Discussion

12.45 Lunch

13.45 Other essential considerations

  • Authorised representatives – Increased responsibilities and requirements
  • Single registration numbers for all economic operators
  • New categories
  • Single use devices – Reprocessing?
    Dr David Jefferys

14.45 Discussion

14.50 Refreshments

15.15 Other essential considerations (continued)

  • Unique device identification
  • Safety and clinical performance summaries
  • Strategies to address the new requirements
    Dr David Jefferys

16.15 Panel discussion and key take home messages

16.30 Close of forum


Janette Benaddi (25-26 Sep 2018)

Janette Benaddi is an Independent Consultant and previously Director of Clinical & Consulting Europe for NAMSA. NAMSA is a global Medical Research Organization offering a breadth of services form preclinical to post market activities throughout the medical device product development cycle.

She has over 20 years’ experience of managing pre and post market clinical studies in both devices and pharmaceuticals. She has worked with several multinational organizations in various clinical, regulatory and marketing roles. She has extensive experience of conducting clinical studies with medical device products as well as regulatory expertise for CE marking of devices.

She is a registered nurse, has a BSc in Management studies, a Diploma in Company Direction and a Diploma in Management studies, she holds a teaching certificate and is a Chartered Scientist and Chartered Director. Janette sits on several committees in the device community and industry and has been an instrumental advocate of improving and advancing medical device research in the UK. She has published several articles relating to medical device regulation and clinical studies.

David Jefferys (25-26 Sep 2018)

Dr David Jefferys is currently Senior Vice President with Eisai responsible for Global Regulatory, Government Relations, Public Affairs and Patient Safety (EMEA, Russia and Australasia). After qualifying in medicine he worked in clinical and academic medicine, before spending 20 years as a senior regulator for both medicines and medical devices. He was executive director of the UK Medicines Control Agency, CEO and Director of the MDA, joint CEO of MHRA. He was involved in the establishment of the European Medicines Agency, CPMP/CHMP member and MRFG and PER scheme chairman. For the last ten years he has worked in industry and chairs several key committees for ABPI, Efpia and IFPMA. He has lectured and published extensively in drug and device regulation and on benefit risk evaluation.

Theresa Jeary (25-26 Sep 2018)

Theresa Jeary is Head of the Notified Body for Medical Devices at LRQA, where she is responsible for Devices Drug products and Class III Medical Conformity Assessment for a wide range of medical devices including In-Vitro Fertilization Media and Solutions for Organ Preservation. She has over 25 years’ experience working in both the Pharmaceutical and Medical Device industries and has worked in a variety of roles across the full development cycle from product concept and early stage development, process transfer, validation and regulatory departments, and has been a part of the team for many commercially available medicinal and medical device products.

Theresa first introduction to the Medical device Industry was as the R&D Manager for a medical device manufacturer, with responsibility for the development of several device drug combination products, with the core technology utilizing bovine collagen. Having been impressed by the innovative nature and speed of development in the Medical Device Industry, she then pursued a move to the other side of the “fence” and into the Notified Body world of Conformity Assessment. First, at BSI as a Certification Manager in the General Device group, and now with Lloyds Register Quality Assurance (LRQA).

Over the years, she has conducted many successful consultations with a large number of the European Competent Authorities as well as the European Medicines Agency (EMA) as well as reviewing the classification of borderline products. She holds a Master’s Degree in Pharmaceutical Science and is eligible to be a Pharmaceutical Qualified Person.

Book now

25-26 Sep 2018
25-26 Sep 2018 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now
5-6 Mar 2019
5-6 Mar 2019 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
  • Bayer Medical Care BV
  • Bayer Pharma AG
  • Becton Dickinson
  • Besins Healthcare Pharma Services Ltd
  • Bristows LLP
  • Cook Medical
  • Edwards Lifesciences
  • Geistlich Pharma
  • Grünenthal GmbH
  • Johnson & Johnson Medical Ltd.
  • Kimberly-Clark Europe Ltd
  • Latham & Watkins
  • LEO Pharma A/S
  • Magstim Company Ltd.
  • Medochemie ltd
  • Medtrade Products Ltd
  • Mundipharma International Services Ltd
  • NDA Regulatory Science Ltd
  • Precipio Consulting
  • Proctor & Gamble Technical Centres Ltd
  • Saudi Food and Drug Authority
  • sphere medical ltd
  • Xiros Ltd

Very good.

Marie-Cécile Lerat, RA Manager MPS Europe, Becton Dickinson

This was an excellent introduction to the Medical Device Regulation, focussing on the key changes and considerations to prepare for compliance with the new requirements. The experienced speakers provided much needed guidance and expertise.

Kate Cole, Regulatory Affairs Manager, Xiros Ltd

The speakers were very knowledgeable and lovely people and on the forefront of the devices industry. The presentations were very clear and interactive. The course was excellent and I would highly recommend to anyone wanted to learn about the new MDR.

Daniel Terzian, Project Assistant, NDA Regulatory Science Ltd

Excellent, both content and speaker line up

Zinovia Chatzidimitriadou, Associate, Bristows LLP

Great content

Andrew Whitton, , Medtrade Products Ltd

Good interactions and good speakers

Katja Gauci, Device Quality Engineer, Mundipharma International Services Ltd

The speakers all did a great job, they were committed and inspiring.

Dorte Reland, Director, PV Operations, LEO Pharma A/S